Cellular senescence mediates fibrotic pulmonary disease
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index; 18 of the 31 sources its claims cite were checked for support.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by interstitial remodelling, leading to compromised lung function. Cellular senescence markers are detectable within IPF lung tissue and senescent cell deletion rejuvenates pulmonary health in aged mice. Whether and how senescent cells regulate IPF or if their removal may be an efficacious intervention strategy is unknown. Here we demonstrate elevated abundance of senescence biomarkers in IPF lung, with p16 expression increasing with disease severity. We show that the secretome of senescent fibroblasts, which are selectively killed by a senolytic cocktail, dasatinib plus quercetin (DQ), is fibrogenic. Leveraging the bleomycin-injury IPF model, we demonstrate that early-intervention suicide-gene-mediated senescent cell ablation improves pulmonary function and physical health, although lung fibrosis is visibly unaltered. DQ treatment replicates benefits of transgenic clearance. Thus, our findings establish that fibrotic lung disease is mediated, in part, by senescent cells, which can be targeted to improve health and function.
Overview
CoChat Summary
## TL;DR
This study links cellular senescence to idiopathic pulmonary fibrosis (IPF) by showing that senescence markers rise with disease severity in human lung tissue and that senescent fibroblast secretions are profibrotic. In a bleomycin mouse model, clearing senescent cells improved lung function and physical health, and dasatinib plus quercetin (DQ) reproduced the benefits of transgenic senescent-cell ablation.
## Key findings
- In human IPF lung samples, CDKN2A (p16) was significantly upregulated and increased with disease severity; higher pulmonary p16 expression correlated with reduced FVC, diffusion capacity, and SF-12 physical component score.
- In IPF tissue, p16-positive epithelial cells and fibroblasts were found in fibroblastic foci and honeycomb lung, and TAF-positive cells / γH2A.X foci were significantly increased relative to controls.
- In the bleomycin mouse model, lung injury increased whole-lung p16 expression by threefold, and SASP-related transcripts including Mcp1, Il6, Mmp12, Col1a1, and Tgfβ rose after bleomycin exposure.
- Senescent fibroblast conditioned medium was fibrogenic in vitro: it increased αSMA positivity to 62% vs 21% with control conditioned medium, increased traction forces, and induced fibrosis genes such as ACTA2, COL1A1, COL1A2, and FN1.
- In mice, senescent-cell clearance improved pulmonary/physical outcomes: Penh rose about twofold after bleomycin and was diminished by AP or DQ; lung compliance fell by 40% in vehicle-treated bleomycin mice but only 15% with AP or DQ; body weight loss averaged 3.6 g with vehicle vs about 1.6 g with AP/DQ; treadmill distance to exhaustion was >37% further with AP/DQ than vehicle.
- The paper states that histological fibrosis reductions did not reach statistical significance, despite functional benefits.
## Methods
- Human data came from LTRC control and IPF lung tissue samples, including microarray and RNA-seq datasets; the paper reports IPF n=27 and control n=10 for p16 immunohistochemistry, and transcriptome analyses stratified by FVC severity.
- The mouse study used male Ink-Attac mice given aerosolized intratracheal bleomycin (2 U/kg) or PBS, then randomized to AP20187, dasatinib plus quercetin (DQ), or vehicle at either an early prevention timepoint or a later treatment timepoint.
- Analyses included FACS of lung fibroblasts, epithelial cells, and endothelial cells, immunohistochemistry / immunofluorescence, conditioned-medium assays in IMR90 fibroblasts, traction force microscopy, RT-PCR, and statistical modeling with regression and multiple-comparison correction.
## Limitations
- The paper states that the bleomycin model spontaneously resolves, with resolution varying by factors such as genetic background and microbiome, which limits interpretation of late-stage effects.
- The authors state that they could not disentangle senescence-dependent from senescence-independent events governing fibrosis resolution.
- Lung fibrosis histology did not improve significantly after senescent-cell clearance, despite functional gains; the paper itself notes this may reflect the short time course and heterogeneity of the bleomycin model.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
13 Valid · 0 Not valid · 8 Not checked · 94 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Through secretion of the senescence-associated secretory phenotype (SASP), a broad repertoire of cytokines, chemokines, matrix remodelling proteases and growth factors, senescent cells paracrinely promote proliferation and tissue deterioration8.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
In “Senescence is a multi-step evolving process” (page unavailable), the paper says SASP-mediated paracrine signalling affects cell proliferation. In “Senescence in ageing and age-related disease” (page unavailable), it says SASP components are thought to promote proliferation of neoplastic cells and may intensify age-related tissue deterioration. The citing sentence presents those qualified effects as established and general. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cellular senescence is an evolutionarily conserved state of stable replicative arrest induced by pro-ageing stressors also implicated in IPF pathogenesis, including telomere attrition, oxidative stress, DNA damage and proteome instability.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
The Abstract and 'Senescence is a multi-step evolving process' describe growth arrest, including a transition to stable cell-cycle arrest. 'Causes and effector pathways of senescence' identifies telomere erosion, DNA lesions, reactive oxygen species and proteotoxic stress as senescence-related stressors. The cited passages do not establish that senescence is evolutionarily conserved or that these stressors are implicated in IPF pathogenesis; the paper also distinguishes replicative senescence from other forms of senescence. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > Senescent cell retention impairs fibrosis resolution Taken together, our in vivo results strongly support the hypothesis that elimination of senescent cells improves fibrotic pulmonary disease when treatment is initiated at the onset of pathogenesis. We next sought to test the clinically important question of whether senescent cell clearance provides comparable benefit when initiated at a timepoint when pathology has fully developed. Ink-Attac mice contained a strong senescent signature in lung fibroblasts and epithelial cells 2 weeks post-bleomycin challenge (Fig. 2), a timepoint of well-established fibrotic remodelling in the lung15. Accordingly, we administered a single dose of bleomycin or PBS through aerosolized intratracheal administration to Ink-Attac mice. Two weeks post challenge, we randomized bleomycin-exposed mice to AP, DQ or vehicle treatment groups based on change in body weight and non-invasively measured airway resistance (Penh). Mice were treated for 2 weeks and were killed 4 weeks following bleomycin or PBS exposure (Fig. 5a). Body weight monitoring revealed that, similar to our previous experiments (Fig. 4f), mice that received bleomycin lost substantial body mass, relative to mice that received PBS. Upon treatment initiation on day 14, mean body weight of mice treated with AP plateaued, while vehicle-treated, bleomycin-exposed counterparts continued to lose weight (Fig. 5a), suggestive of physical benefit afforded by senescent cell clearance, even when treatment is initiated in later-stage disease. Spontaneous resolution is an inherent limitation of the bleomycin IPF model, with the rate and variability of bleomycin-induced pathology resolution dependent on complex factors, including genetic background and the microbiome3839. Indeed, both endpoint compliance (Supplementary Fig. 6) and comparison of Penh airway resistance at endpoint (4 weeks post challenge) to measures taken at the treatment randomization timepoint (2 weeks post challenge) revealed appreciable, albeit variable, improvement in all bleomycin-exposed groups, including vehicle-treated mice, with AP-treated mice showing greatest improvement (Fig. 5b). Thus, in our hands, the 3–4-week-period following a single bleomycin exposure represents a pivotal window of natural resolution (Figs 4 and 5a,b). Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3. As we were unable to disentangle senescence-dependent and -independent events governing resolution, we queried whether p16 expression, a measure of senescent burden, was associated with indicators of disease persistence. Impaired lung function, as measured by endpoint airway resistance (Penh) (Fig. 5c) and airway compliance (Fig. 5d), correlated significantly with p16 transcript abundance. This finding is consistent with associations drawn in humans, in which increased p16 expression correlated significantly with reduced FVC, pulmonary diffusion capacity and physical function (Supplementary Fig. 1). Similarly, in bleomycin-exposed mice, expression of the inflammatory and fibrogenic SASP factors Mcp1 (Fig. 5e), Pai1 (Fig. 5f), Mmp10 (Fig. 5g) and Col1a1 (Fig. 5h) robustly correlated with p16 transcriptional activation. These results further support the notion that the presence and activities of senescent cells may dictate resolution capacity following bleomycin-induced pathology.
What the sources say
- Supportedcites [3] Hecker, L. et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci. Transl. Med. 6, 231ra247 (2014). source
The Introduction states that aged mice have impaired fibrosis resolution associated with senescent, apoptosis-resistant myofibroblasts. The Results identify bleomycin as the lung-injury model and report accumulation of senescent myofibroblasts in aged mice with persistent fibrosis. Page numbers are not provided in our copy. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation.”
§ Cellular senescence mediates fibrotic pulmonary disease > Methods > Cell culture For experiments employing radiation-induced senescence, IMR90 (passages 5–7; ATCC, catalogue number CCL-186) and primary human fibroblasts (passages 3–6) were exposed to 10 Gy radiation or sham conditions using a RS2000 X-Ray Irradiator (RAD Source Technologies, Suwanee, GA). Normal bronchial epithelial cells (passages 4–7, Lot 7F3000, Lonza, Walkersville, MD) were exposed to 5 Gy or sham conditions. Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation. For SA-β-gal staining, cells were fixed for 10 min in 2% formaldehyde+0.2% glutaraldehyde in PBS at room temperature. Cells were rinsed with PBS and incubated overnight in SA-β-gal staining solution containing the following: 1 mg ml−1 X-gal, 40 mM citric acid/sodium phosphate buffer pH 6.0, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM sodium chloride and 2 mM magnesium chloride in water. Cells were then rinsed in PBS and stored at 4 °C until imaging. Media applied 20 days post irradiation (or sham) was collected 24 h later and was diluted with NCM to reflect equivalent source cell concentrations. ProcartaPlex immunoassays (Affymetrix eBioscience) were used for CM secretome composition assessment, according to the manufacturer's specifications. Non-irradiated IMR90 cells (passages 5–7) were treated with NCM, NCM+2 ng ml−1 TGFβ, CCM or SASP-CM and applied to downstream analyses as indicated. Primary human fibroblasts collected from human patients were authenticated through αSMA staining. For senolytic treatment, sham and irradiated primary human fibroblasts were treated with indicated concentrations of DQ or navitoclax for 3 days, starting at day 20 post irradiation or sham exposure. Cell viability after drug treatment was measured by ATPLite Kits (PerkinElmer; Waltham, MA) performed according the manufacturer's instructions. Luminescence was read using a multi-scan plate reader (Fisher). For experiments utilizing etoposide-induced senescence, IMR90 human lung fibroblasts (passage 10; ATCC) were treated for 48 h with 20 μM etoposide (Enzo Life Sciences, Farmingdale, NY). Etoposide was removed and replaced with fresh media. Six days after etoposide removal, approximately 60% of IMR90 cells were SA-β-gal positive. Cells were treated for 48 h with 20 μM D+15 μM Q or 10 μM navitoclax (or untreated control) and the percentage of SA-β-gal-positive cells was determined using a C12FDG-based senescence assay described as follows46. Briefly, etoposide-treated senescent IMR90 cells were seeded at a concentration of 5 × 103 cells per well in 96-well plates 24 h before treatment. Following addition of the drugs, the cells were incubated for 48 h under 20% O2 oxygen conditions. For fluorescence analysis of SA-β-gal activity, cells were incubated for 1 h with 100 nM Bafilomycin A1 (Calbiochem, San Diego, CA). Next, 10 μM C12FDG (Setareh Biotech, Eugene, OR) was added to the culture medium and the cells were incubated for 1.5–2 h. Ten minutes before analysis, the DNA intercalating Hoechst dye (2 μg ml−1) was added to the cells. For quantitative analysis of cell number (Hoechst staining) and number of C12FDG-positive senescent cells, a laser-based line scanning confocal imager IN Cell 6000 Analyzer was used. All samples were analysed in duplicate with three to five fields per well.
What the sources say
- Partly supportedcites [32] Baker, D. J. et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184–189 (2016). sourceExperimental — accuracy not yet measured
In “ATTAC clears senescent adipocyte progenitor cells” (page unavailable), the paper identifies cells using p16 expression, other senescence markers, and SAβ-Gal staining. It studies naturally occurring senescent cells, however, and does not support the claim’s 21-day post-radiation condition. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, CM collected from irradiated bronchiolar epithelial cells did not activate a fibrogenic response, as measured by αSMA fibrotic activation of naive IMR90 cells (Supplementary Fig. 2), suggesting that cell-type-specific SASP composition may differentially affect pathological phenotypes within the lung.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > The secretome of senescent fibroblasts is profibrotic
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
61 more claims
Create a free account to see all 115 claims and to verify the 5 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is in agreement with a recent report showing that the removal of senescent cells expressing high levels of p16INK4a can lead to fibrosis in mice101, whereas small-molecule senolytics appear to reduce fibrosis in several mouse tissues22,71,73,75,102.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in a mouse model of idiopathic pulmonary fibrosis (IPF), D + Q treatment improved lung compliance and reduced frailty71.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with IPF accumulate TAFs and senescence markers in lungs that increase with disease severity and activate SASP52.”
From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of various natural flavonoids, including quercetin and fisetin, either alone or in combination with dasatinib, a pan-tyrosine kinase inhibitor, can stimulate senolysis in a variety of contexts in vitro and in vivo199,207–210.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“consistent with enhanced paracrine signaling from increased numbers of senescent neighbors and with established features of epithelial aging.23,25,32–35”
From SenCat: Cataloging human cell senescence through multi-omic profiling of multiple senescent primary cell types (2026) · cites this paper as [33]
Experimental — accuracy not yet measured
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Self-citationNaturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876 · cited 2×
“Attenuation of age-related pathologies and extension of lifespan in chronologically aged mice has been demonstrated using the same transgenic strategy 32–34 , and improvements in lung structure and function in aged mice have recently been demonstrated using a similar suicide-gene strategy 20 .”
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584 · cited 2×
“An alternative approach to transgenic senescent cell clearance is senolytics 21,22 , which may be a tractable treatment option for humans.”
Self-citationDesmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA
Demaria, M., Ohtani, N., Youssef, S. A., Rodier, F., Toussaint, W., Mitchell, J. R., Laberge, R.-M., Vijg, J., Van Steeg, H., Dollé, M. E. T., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.11.012 · Cited by 2,045
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Cited by
Items 301–400 of 1,619
Emerging insights in senescence: pathways from preclinical models to therapeutic innovations
Mansfield, L., Ramponi, V., Gupta, K., Stevenson, T., Mathew, A. B., Barinda, A. J., Herbstein, F., & Morsli, S. (2024) · npj Aging · doi:10.1038/s41514-024-00181-1 · Cited by 88
Mitochondria and cellular senescence: Implications for musculoskeletal ageing
Habiballa, L., Salmonowicz, H., & Passos, J. F. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.417 · Cited by 82
Self-citationVazquez‐Villaseñor, I., Garwood, C. J., Heath, P. R., Simpson, J. E., Ince, P. G., & Wharton, S. B. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12559 · Cited by 82
Cellular senescence links mitochondria-ER contacts and aging
Ziegler, D. V., Martin, N., & Bernard, D. (2021) · Communications Biology · doi:10.1038/s42003-021-02840-5 · Cited by 98
Loss of IGFBP2 mediates alveolar type 2 cell senescence and promotes lung fibrosis
Chin, C., Ravichandran, R., Sanborn, K., Fleming, T. P., Wheatcroft, S. B., Kearney, M. T., Tokman, S., Walia, R., Smith, M. A., Flint, D. J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100945 · Cited by 106
“8 Cellularsenescence,astressresponseassociatedwithsta-ble cell-cycle arrest, is accompanied by robust secretion of pro-inflammatory mediators leading to senescence-associated secretory phenotype (SASP).”
Rapamycin improves healthspan but not inflammaging in nfκb1−/− mice
Correia‐Melo, C., Birch, J., Fielder, E., Rahmatika, D., Taylor, J., Chapman, J., Lagnado, A., Carroll, B. M., Miwa, S., Richardson, G., et al. (2019) · Aging Cell · doi:10.1111/acel.12882 · Cited by 77
“and has increased frequency of senescent cells under conditions of chronic inflammation (Birch et al., 2015; Schafer et al., 2017).”
BackgroundSelf-citationInvariant natural killer T cells coordinate removal of senescent cells
Arora, S., Thompson, P. J., Wang, Y., Bhattacharyya, A., Apostolopoulou, H., Hatano, R., Naikawadi, R. P., Shah, A., Wolters, P. J., Koliwad, S., et al. (2021) · Med · doi:10.1016/j.medj.2021.04.014 · Cited by 77
DHEA-induced ovarian hyperfibrosis is mediated by TGF-β signaling pathway
Wang, D., Wang, W., Liang, Q., He, X., Xia, Y., Shen, S., Wang, H., Gao, Q., & Wang, Y. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-017-0375-7 · Cited by 79
“Tissue fibrosis is generally considered to arise due to the failure of the normal wound healing or the accumulation of senescence cells [34, 35].”
BackgroundMa, H., Wu, X., Li, Y., & Xia, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.963054 · Cited by 86
Molecular programs of fibrotic change in aging human lung
Lee, S., Islam, M. N., Boostanpour, K., Aran, D., Jin, G., Christenson, S., Matthay, M. A., Eckalbar, W. L., DePianto, D. J., Arron, J. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26603-2 · Cited by 78
Senolytics (DQ) Mitigates Radiation Ulcers by Removing Senescent Cells
Wang, H., Wang, Z., Huang, Y., Zhou, Y., Sheng, X., Jiang, Q., Wang, Y., Luo, P., Luo, M., & Shi, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01576 · Cited by 78
“Therefore, we assessed the effect of DQ, which has been reported to selectively clear senescent cells (11, 19, 20).”
BackgroundThe interactions and communications in tumor resistance to radiotherapy: Therapy perspectives
Ashrafizadeh, M., Farhood, B., Musa, A. E., Taeb, S., & Najafi, M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106807 · Cited by 81
Cellular senescence and the host immune system in aging and age-related disorders
Giannoula, Y., Kroemer, G., & Pietrocola, F. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.02.001 · Cited by 79
“[42] Schafer MJ, White TA, Iijima K, Haak AJ, Ligresti G, Atkinson EJ, et al.”
BackgroundThe YAP-TEAD complex promotes senescent cell survival by lowering endoplasmic reticulum stress
Anerillas, C., Mazan-Mamczarz, K., Herman, A. B., Munk, R., Lam, K.-W. G., Calvo-Rubio, M., Garrido, A., Tsitsipatis, D., Martindale, J. L., Altés, G., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00480-4 · Cited by 76
Antiaging effects of bioactive molecules isolated from plants and fungi
Martel, J., Ojcius, D. M., Ko, Y., Chang, C., & Young, J. D. (2019) · Medicinal Research Reviews · doi:10.1002/med.21559 · Cited by 81
“Desatinib and quercetin also reduced senescent cell accumulation in the lungs, inflammation, fibrosis, and respiratory dysfunctions in a model of bleomycin‐induced pulmonary fibrosis.(226) The field of senolytics is relatively new and more studies will be needed to determine the possibility of using such treatments to…”
BackgroundMalavolta, M., Bracci, M., Santarelli, L., Sayeed, M. A., Pierpaoli, E., Giacconi, R., Costarelli, L., Piacenza, F., Basso, A., Cardelli, M., et al. (2018) · Mediators of Inflammation · doi:10.1155/2018/4159013 · Cited by 81
“Preclinical studies have reported that senolytic compounds can improve cardiac function [38] in old mice, recover vascular function and decrease vascular calcification in atherosclerosis mice [39], and improve pulmonary function and physical health in mouse models of fibrotic pulmonary disease [40], as well as achieve…”
Telomere dysfunction promotes transdifferentiation of human fibroblasts into myofibroblasts
Razdan, N., Vasilopoulos, T., & Herbig, U. (2018) · Aging Cell · doi:10.1111/acel.12838 · Cited by 74
IGFBP-2 Signaling in the Brain: From Brain Development to Higher Order Brain Functions
Khan, S. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00822 · Cited by 86
“On the other hand, fibrotic lung disease is characterized by the presence of senescent cells, where IGFBP-2 expression was moderately high (91).”
BackgroundCellular Senescence in Lung Fibrosis
Hernandez-Gonzalez, F., Faner, R., Rojas, M., Agustí, A., Serrano, M., & Sellarés, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137012 · Cited by 76
“However, when the combined treatment was tested in mice with established lung fibrosis after 2–4 weeks of bleomycin administration, the expression of inflammatory markers was diminished, but attenuation of lung fibrosis failed [69].”
BackgroundCellular senescence in asthma: from pathogenesis to therapeutic challenges
Wan, R., Srikaram, P., Guntupalli, V., Hu, C., Chen, Q., & Gao, P. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104717 · Cited by 91
Epithelial Injury and Dysfunction in the Pathogenesis of Idiopathic PulmonaryFibrosis
Winters, N. I., Burman, A., Kropski, J. A., & Blackwell, T. S. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.01.010 · Cited by 76
Fibrotic pathways and fibroblast-like synoviocyte phenotypes in osteoarthritis
Damerau, A., Rosenow, E., Alkhoury, D., Buttgereit, F., & Gaber, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1385006 · Cited by 95
Compromised DNA repair is responsible for diabetes‐associated fibrosis
Kumar, V., Agrawal, R., Pandey, A., Kopf, S., Höffgen, M., Kaymak, S., Bandapalli, O. R., Gorbunova, V. A., Seluanov, A., Mall, M. A., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019103477 · Cited by 78
“…fibrosis (Toussaint et al , 2002; Narita et al , 2006; Rodier et al , 2009; Freund et al , 2010; O’Driscoll, 2012; Cheresh et al , 2013; Chilosi et al , 2013; Tchkonia et al , 2013; Pove-dano et al , 2015; Kumar et al , 2017; Schafer et al , 2017, 2018; Keijzers et al , 2018; Rivera et al , 2018).”
Targeting senescent cells improves functional recovery after spinal cord injury
Paramos-de-Carvalho, D., Martins, I., Cristóvão, A. M., Dias, A. F., Neves-Silva, D., Pereira, T., Chapela, D., Farinho, A., Jacinto, A., & Saúde, L. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109334 · Cited by 74
Targeting cellular senescence in metabolic disease
Palmer, A. K., Tchkonia, T., & Kirkland, J. L. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101601 · Cited by 79
Self-citationRaslan, A., Pham, T. X., Lee, J., Kontodimas, K., Tilston-Lünel, A., Schmottlach, J., Hong, J., Dinc, M. T., Bujor, A. M., Caporarello, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49545-x · Cited by 99
Self-citationTargeting Fibrosis: From Molecular Mechanisms to Advanced Therapies
Di, X., Li, Y., Wei, J., Li, T., & Liao, B. (2024) · Advanced Science · doi:10.1002/advs.202410416 · Cited by 121
Roy, B. (2025) · Medical Sciences · doi:10.3390/medsci13030087 · Cited by 129
The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis
Platé, M., Guillotin, D., & Chambers, R. C. (2020) · European Respiratory Review · doi:10.1183/16000617.0269-2020 · Cited by 76
Senescent cells as promising targets to tackle age-related diseases
Prašnikar, E., Borišek, J., & Perdih, A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101251 · Cited by 73
The Emergence of Senescent Surface Biomarkers as Senotherapeutic Targets
Rossi, M., & Abdelmohsen, K. (2021) · Cells · doi:10.3390/cells10071740 · Cited by 71
Cellular Plasticity: A Route to Senescence Exit and Tumorigenesis
De Blander, H., Morel, A.-P., Senaratne, A. P., Ouzounova, M., & Puisieux, A. (2021) · Cancers · doi:10.3390/cancers13184561 · Cited by 72
Heterochronic parabiosis regulates the extent of cellular senescence in multiple tissues
Yousefzadeh, M. J., Wilkinson, J. E., Hughes, B., Gadela, N., Ladiges, W. C., Vo, N., Niedernhofer, L. J., Huffman, D. M., & Robbins, P. D. (2020) · GeroScience · doi:10.1007/s11357-020-00185-1 · Cited by 70
Self-citationCellular senescence in age-related disorders
Kaur, J., & Farr, J. N. (2020) · Translational research · doi:10.1016/j.trsl.2020.06.007 · Cited by 84
“For example, senolytic therapy in mouse models of aging and disease has been shown to extend healthspan by preventing or alleviating the following: osteoporosis,(27) frailty,(48) atherosclerosis,(28,49) hepatic steatosis,(50) osteoarthritis,(32) idiopathic pulmonary fibrosis,(51) obesity-induced anxiety,(52) tau-media…”
InfluentialKhanna, D., Padilla, C. M., Tsoi, L. C., Nagaraja, V., Khanna, P. P., Tabib, T., Kahlenberg, J. M., Young, A., Huang, S., Gudjonsson, J. E., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159566 · Cited by 91
“Senescence contributes importantly to lung fibrosis (53) and is associated with mitochondrial dysfunction (54) but also with OxPhos (55).”
Frailty index as a biomarker of lifespan and healthspan: Focus on pharmacological interventions
Palliyaguru, D. L., Moats, J. M., Di Germanio, C., Bernier, M., & de Cabo, R. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.03.005 · Cited by 71
“In another study, AP20187 and a combination of dasatinib and quercetin were shown to improve running time in bleomycin-treated mice that exhibited lung fibrosis through alleviation of senescence [56].”
BackgroundTherapeutic Potential of Senolytics in Cardiovascular Disease
Dookun, E., Passos, J. F., Arthur, H. M., & Richardson, G. D. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07075-w · Cited by 69
“While initially this data would suggest that elimination of senescence post-MI would only have detrimental effects, inhibition of senescence post-MI also attenuated inflammation and reduced the expression of SASP associated cytokines such as interleukin (IL) 1, chemokine ligand 1, chemokine ligand 2, IL6, granulocyte…”
BackgroundSelf-citationTian, Y., Lv, J., Su, Z., Wu, T., Li, X., Hu, X., Zhang, J., & Wu, L. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106685118 · Cited by 76
“cellular senescence in bleomycin-treated LRRK2-deficient mice are of particular interest because epithelial cell senescence has been regarded as one of the hallmarks of pulmonary fibrosis (51).”
BackgroundResultZhang, T., Tong, X., Zhang, S., Wang, D., Wang, L., Wang, Q., & Fan, H. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.731453 · Cited by 81
Flores, A., Gerónimo‐Olvera, C., Girardi, K. D. C. D. V., Ñecuñir, D., Patel, S. K., Bons, J., Wright, M. C., Geschwind, D. H., Höke, A., Gomez-Sanchez, J. A., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202317907 · Cited by 90
“This affects neighboring cells in a paracrine fashion, leading to tissue dysfunction or age-related pathologies (Mu ~ noz-Esp (cid:1) ın & Serrano, 2014; Childs et al , 2015; Schafer et al , 2017; Rhinn et al , 2019).”
BackgroundFielder, E., Wan, T., Alimohammadiha, G., Ishaq, A., Low, E., Weigand, B. M., Kelly, G., Parker, C., Griffin, B., Jurk, D., et al. (2022) · eLife · doi:10.7554/elife.75492 · Cited by 70
Basisty, N., Kale, A., Patel, S., Campisi, J., & Schilling, B. (2020) · Expert Review of Proteomics · doi:10.1080/14789450.2020.1766976 · Cited by 69
“aracts [35], diabetes [36], metabolic syndrome [37], pulmonary fibrosis [38], osteoarthritis [39], osteoporosis [40], and sarcopenia/frailty [41], among others.”
BackgroundSTAT3 Regulates the Onset of Oxidant-induced Senescence in Lung Fibroblasts
Waters, D. W., Blokland, K. E. C., Pathinayake, P. S., Wei, L., Schuliga, M. J., Jaffar, J., Westall, G. P., Hansbro, P. M., Prêle, C. M., Mutsaers, S. E., et al. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0328oc · Cited by 77
p16 a biomarker of aging and tolerance for cancer therapy
Muss, H. B., Smitherman, A., Wood, W. A., Nyrop, K., Tuchman, S., Randhawa, P. K., Entwistle, A. R., Mitin, N., & Shachar, S. S. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.03.39 · Cited by 69
“Nearly all of the compelling animal data cited above, including evidence for a causal role for senescence in age-related diseases, has been generated using experimental models in which senescence is defined by expression of the p16 biomarker (35-37,44-49).”
BackgroundMisawa, T., Tanaka, Y., Okada, R., & Takahashi, A. (2020) · Geriatrics & Gerontology International · doi:10.1111/ggi.13928 · Cited by 69
CD38 Mediates Lung Fibrosis by Promoting Alveolar Epithelial Cell Aging
Cui, H., Xie, N., Banerjee, S., Dey, T., Liu, R.-M., Antony, V. B., Sanders, Y. Y., Adams, T. S., Gómez, J. L., Thannickal, V. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202109-2151oc · Cited by 76
Zhang, L., Zhang, J., Zhang, Y., Fei, C., Wang, L., Yi, Z.-W., & Zhang, Z. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108756 · Cited by 75
Endothelial Senescence: A New Age in Pulmonary Hypertension
Culley, M. K., & Chan, S. Y. (2022) · Circulation Research · doi:10.1161/circresaha.121.319815 · Cited by 75
Emerging Roles of Airway Epithelial Cells in Idiopathic Pulmonary Fibrosis
Chakraborty, A., Mastalerz, M., Ansari, M., Schiller, H. B., & Staab-Weijnitz, C. A. (2022) · Cells · doi:10.3390/cells11061050 · Cited by 68
The impact of senescence on muscle wasting in chronic kidney disease
Huang, Y., Wang, B., Hassounah, F., Price, S. R., Klein, J., Mohamed, T. M. A., Wang, Y., Park, J., Cai, H., Zhang, X., et al. (2023) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13112 · Cited by 70
“In earlier reports, a senolytic cocktail consisting of dasatinib plus quercetin (D&Q) selectively eliminated senescent cells in vivo and in vitro.(18,22) To investigate the relationship between CKD-induced cellular senescence and muscle atrophy, CKD mice were administered D&Q twice a week for 8 weeks and muscles were…”
BackgroundTargeting senescent cells with NKG2D-CAR T cells
Deng, Y., Kumar, A., Xie, K., Schaaf, K., Scifo, E., Morsy, S., Li, T., Ehninger, A., Bano, D., & Ehninger, D. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01976-7 · Cited by 75
Loss of Ovarian Hormones and Accelerated Somatic and Mental Aging
Rocca, W. A., Rocca, L. G., Smith, C. Y., Grossardt, B. R., Faubion, S. S., Shuster, L. T., Kirkland, J. L., LeBrasseur, N. K., Schafer, M. J., Mielke, M. M., et al. (2018) · Physiology · doi:10.1152/physiol.00024.2018 · Cited by 80
Self-citationNADPH oxidases: Pathophysiology and therapeutic potential in age-associated pulmonary fibrosis
Kato, K., & Hecker, L. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101541 · Cited by 70
Lipotoxicity, aging, and muscle contractility: does fiber type matter?
Carter, C. S., Justice, J. N., & Thompson, L. (2019) · GeroScience · doi:10.1007/s11357-019-00077-z · Cited by 66
The cellular mechanobiology of aging: from biology to mechanics
Bajpai, A., Li, R., & Chen, W. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14529 · Cited by 76
Increased expression and accumulation of GDF15 in IPF extracellular matrix contribute to fibrosis
Radwańska, A., Cottage, C. T., Piras, A., Overed-Sayer, C. L., Sihlbom, C., Budida, R., Wrench, C., Connor, J., Monkley, S. J., Hazon, P., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.153058 · Cited by 72
“IPF is linked to both fibroblast senescence and epithelial cell senescence (26).”
Cellular Senescence in Idiopathic Pulmonary Fibrosis
Kellogg, D. L., Kellogg, D. L., Musi, N., & Nambiar, A. M. (2021) · Current Molecular Biology Reports · doi:10.1007/s40610-021-00145-4 · Cited by 67
Mavrogonatou, E., Papadopoulou, A., Pratsinis, H., & Kletsas, D. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00178.2023 · Cited by 66
Therapeutic targeting of senescent cells in the CNS
Riessland, M., Ximerakis, M., Jarjour, A. A., Zhang, B., & Orr, M. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01033-z · Cited by 77
Cell Senescence, Multiple Organelle Dysfunction and Atherosclerosis
Machado-Oliveira, G., Ramos, C., Marques, A. R. A., & Vieira, O. V. (2020) · Cells · doi:10.3390/cells9102146 · Cited by 80
Herrera, J. A., Dingle, L., Montero, M. A., Venkateswaran, R. V., Blaikley, J. F., Lawless, C., & Schwartz, M. A. (2022) · JCI Insight · doi:10.1172/jci.insight.156115 · Cited by 64
“PDLIM7 regulates cellular senescence (72), a process that likely contributes to IPF (73).”
BackgroundImmunosenescence in atherosclerosis: A role for chronic viral infections
Talepoor, A. G., & Doroudchi, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945016 · Cited by 71
Accelerated Vascular Aging in Chronic Kidney Disease: The Potential for Novel Therapies
Hobson, S., Arefin, S., Witasp, A., Hernandez, L. N., Kublickiene, K. R., Shiels, P. G., & Stenvinkel, P. (2023) · Circulation Research · doi:10.1161/circresaha.122.321751 · Cited by 72
Chung, E. J., Kwon, S., Reedy, J. L., White, A. O., Song, J. S., Hwang, I., Chung, J., Ylaya, K., Hewitt, S. M., & Citrin, D. E. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.12.035 · Cited by 66
Senescence in chronic wounds and potential targeted therapies
Wei, X., Li, M., Zheng, Z., Ma, J., Gao, Y., Chen, L., Peng, Y., Yu, S., & Yang, L. (2021) · Burns & Trauma · doi:10.1093/burnst/tkab045 · Cited by 72
“In the idiopathic pulmonary fibrosis model induced by bleomycin, the combination use of dasatinib and quercetin can selectively kill senescent fibroblasts [116].”
BackgroundDNA repair as a shared hallmark in cancer and ageing
Clarke, T. L., & Mostoslavsky, R. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13285 · Cited by 84
Sarcoidosis deaths in the United States: 1999–2016
Kearney, G. D., Obi, O. N., Maddipati, V., Mohan, A., Malur, A., Carter, J. C., & Thomassen, M. J. (2018) · Respiratory Medicine · doi:10.1016/j.rmed.2018.11.010 · Cited by 65
Hadjicharalambous, M. R., Roux, B. T., Feghali‐Bostwick, C. A., Murray, L. A., Clarke, D. L., & Lindsay, M. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02906 · Cited by 70
“data of biopsy samples obtained from control (n = 19) and IPF (n = 20) lungs (Table S4) (36).”
BackgroundTargeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option
Korfei, M., Mahavadi, P., & Guenther, A. (2022) · Cells · doi:10.3390/cells11101626 · Cited by 72
“In addition, this senolytic cocktail was also shown to attenuate bleomycin-induced lung fibrosis in mice [121].”
BackgroundThe Spectrum of Reactive Cholangiocytes in Primary Sclerosing Cholangitis
Guicciardi, M. E., Trussoni, C. E., LaRusso, N. F., & Gores, G. J. (2020) · Hepatology · doi:10.1002/hep.31067 · Cited by 62
“(8,9) In a mouse model of idiopathic pulmonary fibrosis, the combination of two senolytic drugs effectively reduced the number of senescent cells in the lung and diminished lung inflammation and fibrosis, suggesting that senotherapeutics could be beneficial in the treatment of senescence-associated fibroinflammatory d…”
BackgroundFarr, J. N., Kaur, J., Doolittle, M. L., & Khosla, S. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00619-x · Cited by 60
Senolytic targets and new strategies for clearing senescent cells
Ge, M., Hu, L., Ao, H.-S., Zi, M., Kong, Q., & He, Y. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111468 · Cited by 67
Khalil, R., Diab‐Assaf, M., & Lemaître, J.-M. (2023) · Cells · doi:10.3390/cells12060915 · Cited by 73
“Mouse studies revealed that senescence contributes to fibrotic pulmonary disease models, as fibrosis was reduced and lung function improved when these mice were treated with senolytics, antiinflammatory molecules, and therapeutic nanoparticles [7,217,261].”
BackgroundEtiology and Pathogenesis of Rheumatoid Arthritis-Interstitial Lung Disease
Kim, Y., Yang, H.-I., & Kim, K. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914509 · Cited by 75
“Lung epithelial cellular senescence orchestrates lung injury by stimulating FMT [120,121].”
BackgroundCOPI vesicle formation and N-myristoylation are targetable vulnerabilities of senescent cells
McHugh, D., Sun, B., Gutierrez-Muñoz, C., Hernández-González, F., Mellone, M., Guiho, R., Duran, I., Pombo, J., Pietrocola, F., Birch, J., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01287-6 · Cited by 59
“To evaluate their senolytic potential, we tested NMTi in models of cancer, NASH and IPF.”
BackgroundInfluentialSelf-citationSenescence and tissue fibrosis: opportunities for therapeutic targeting
O’Reilly, S., Tsou, P., & Varga, J. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.05.012 · Cited by 72
Relationships Between Ion Channels, Mitochondrial Functions and Inflammation in Human Aging
Strickland, M., Yacoubi‐Loueslati, B., Bouhaouala‐Zahar, B., Pender, S. L. F., & Larbi, A. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00158 · Cited by 68
Zhang, C., Duan, J., Yang, H., Sun, C., Zhong, W., Tao, J., Guan, X., Jiang, H., Hammock, B. D., Hwang, S. H., et al. (2019) · FEBS Journal · doi:10.1111/febs.15105 · Cited by 65
Cellular Senescence and Senotherapies in the Kidney: Current Evidence and Future Directions
Docherty, M. H., Baird, D., Hughes, J., & Ferenbach, D. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00755 · Cited by 69
“Both these transgenic models (INK-ATTAC and P16:3MR) have been used to study disease in other organs and have demonstrated benefit post depletion in several models of disease including bone marrow irradiation, tau-mediated neurodegeneration, and bleomycin induced pulmonary fibrosis (Chang et al., 2016; Schafer et al.,…”
BackgroundMethodTargeting Alveolar Repair in Idiopathic Pulmonary Fibrosis
Ptasinski, V., Stegmayr, J., Belvisi, M. G., Wagner, D. E., & Murray, L. A. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0476tr · Cited by 65
“Senolytic compounds, drugs that selectively clear senescent cells, have been shown to be capable of inhibiting pulmonary fibrosis ex vivo and in vivo (16, 54); however, no clinical trials have yet been conducted to test this concept in patients with IPF.”
BackgroundConnective Tissue Growth Factor in Idiopathic Pulmonary Fibrosis: Breaking the Bridge
Effendi, W. I., & Nagano, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116064 · Cited by 60
“Therefore, the clearance of cellular (fibroblast, epithelial, and endothelial) senescence improved lung function and fibrosis resolution [99].”
BackgroundThe dietary antioxidant quercetin reduces hallmarks of bleomycin-induced lung fibrogenesis in mice
Boots, A. W., Veith, C., Albrecht, C., Bartholomé, R., Drittij-Reijnders, M.-J., Claessen, S. M. H., Bast, A., Rosenbruch, M., Jonkers, L., van Schooten, F., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1142-x · Cited by 64
Magkouta, S., Veroutis, D., Pousias, A., Papaspyropoulos, A., Pippa, N., Lougiakis, N., Kambas, K., Lagopati, N., Polyzou, A., Georgiou, M., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.09.006 · Cited by 59
Ageing mechanisms that contribute to tissue remodeling in lung disease
Schuliga, M. J., Read, J. M., & Knight, D. A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101405 · Cited by 64
Cellular Senescence in Aging Lungs and Diseases
Aghali, A., Ngassie, M. L. K., Pabelick, C. M., & Prakash, Y. S. (2022) · Cells · doi:10.3390/cells11111781 · Cited by 69
“Increased expression of p16 along with increased pro-fibrotic SASP has been reported in bleomycin-induced pulmonary fibrosis mouse models [60].”
BackgroundSelf-citationMbara, K. C., Devnarain, N., & Owira, P. M. O. (2022) · Pharmaceutical Medicine · doi:10.1007/s40290-022-00444-w · Cited by 47
Huang, K. Y., Mishra, K., Park, H., Yi, X., Ouyang, J. F., Petretto, E. G., & Behmoaras, J. V. (2023) · eLife · doi:10.7554/elife.85530 · Cited by 74
Moderate hyperoxia induces senescence in developing human lung fibroblasts
You, K., Parikh, P., Khandalavala, K., Wicher, S. A., Manlove, L., Yang, B., Roesler, A., Roos, B. B., Teske, J. J., Britt, R. D., et al. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00067.2019 · Cited by 59
“An important pathological feature of senescent cells is the SASP, and while the SASP of lung fibroblasts in COPD and IPF has previously been described (20, 44), its characterization was limited to the gene expression of a few inflammatory markers.”
BackgroundSelf-citationBlokland, K. E. C., Waters, D. W., Schuliga, M. J., Read, J. M., Pouwels, S. D., Grainge, C., Jaffar, J., Westall, G. P., Mutsaers, S. E., Prêle, C. M., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12040389 · Cited by 64
“Through the SASP senescent cells are able to impact neighboring cells and the local microenvironment [13,14].”
BackgroundSenescence under appraisal: hopes and challenges revisited
Davan-Wetton, C. S. A., Pessolano, E., Perretti, M., & Montero‐Melendez, T. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03746-x · Cited by 64
The Jekyll and Hyde of Cellular Senescence in Cancer
Demirci, D., Dayanc, B., Mazi, F. A., & Şentürk, Ş. (2021) · Cells · doi:10.3390/cells10020208 · Cited by 69
Sun, L., Zhang, X., Wu, S., Liu, Y., Guerrero‐Juarez, C. F., Liu, W., Huang, J., Yao, Q., Yin, M., Li, J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112647 · Cited by 61
Increased cellular senescence in doxorubicin-induced murine ovarian injury: effect of senolytics
Gao, Y., Wu, T., Tang, X., Wen, J., Zhang, Y., Zhang, J., & Wang, S. (2023) · GeroScience · doi:10.1007/s11357-023-00728-2 · Cited by 56
“In addition, short-term intermittent use of DQ after acute injuries such as chemotherapy-induced lung injury and radiation ulcers mitigated the severity of lesions [43, 44].”
BackgroundSelf DNA perpetuates IPF lung fibroblast senescence in a cGAS-dependent manner
Schuliga, M. J., Read, J. M., Blokland, K. E. C., Waters, D. W., Burgess, J. K., Prêle, C. M., Mutsaers, S. E., Jaffar, J., Westall, G. P., Reid, A. T., et al. (2020) · Clinical Science · doi:10.1042/cs20191160 · Cited by 62
“senescent epithelial cells with senolytic compounds attenuates SASP mediators and ECM markers, while increasing expression of alveolar epithelial markers ex vivo [14, 18].”
BackgroundDoolittle, M. L., Saul, D., Kaur, J., Rowsey, J. L., Vos, S. J., Pavelko, K. D., Farr, J. N., Monroe, D. G., & Khosla, S. (2023) · Nature Communications · doi:10.1038/s41467-023-40393-9 · Cited by 57
“Quanti fi ed values were exported to Graphpad Prism 8 to construct plots and perform statistical analyses.”
Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis
Kreuter, M., Costabel, U., Richeldi, L., Cottin, V., Wijsenbeek, M. S., Bonella, F., Bendstrup, E. M., Maher, T. M., Wachtlin, D., Stowasser, S., et al. (2018) · Respiration · doi:10.1159/000486286 · Cited by 61
Doolittle, M. L., Saul, D., Kaur, J., Rowsey, J. L., Vos, S. J., Pavelko, K. D., Farr, J. N., Monroe, D. G., & Khosla, S. (2023) · doi:10.1101/2023.01.12.523760 · Cited by 57
Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies
Selvarajah, B., Platé, M., & Chambers, R. C. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101227 · Cited by 57
Gao, X., Xu, D., Li, S., Wei, Z., Li, S., Cai, W., Mao, N., Jin, F., Li, Y., Xue, Y., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.05.005 · Cited by 58
“Paul, MN, USA) according to published methods.(36) In brief, rats were placed in the chambers and allowed to acclimatize for 10 min before measurements were performed (respiratory parameters are shown in Table S5).”
MethodCheca, J., & Aran, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239317 · Cited by 61
Metadata
- Authors
- Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., Mazula, D. L., Brooks, R. W., Fuhrmann-Stroissnigg, H., Pirtskhalava, T., Prakash, Y. S., Tchkonia, T., Robbins, P. D., Aubry, M. C., Passos, J. F., Kirkland, J. L., Tschumperlin, D. J., Kita, H., & LeBrasseur, N. K.
- Affiliations
- Mayo Clinic (US)
- Newcastle University (GB)
- Scripps Research Institute (US)
- Corresponding author
- LeBrasseur, Nathan K.
- ORCID
- Venue
- Nature Communications
- Published
- 2017-02-23
- Volume
- 8
- Issue
- 1
- Pages
- 14532-14532
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5331226
- OpenAlex
- W2591114726
- Cited by
- 1,613
- References
- 52
- Citations by year
- 2026: 195 · 2025: 205 · 2024: 193 · 2023: 193 · 2022: 192 · 2021: 181 · 2020: 176 · 2019: 128 · 2018: 107 · 2017: 42
- FWCI
- 91.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- Mayo Clinic (UL1-TR000135)
- Glenn Foundation for Medical Research
- Louisiana Transportation Research Center
- Georgia Clinical and Translational Science Alliance (UL1 TR000135)
- Noaber Foundation
- Fondation pour la Recherche Médicale
- National Institutes of Health (UL1TR000135, 2r01hl092961-13)
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council (BB/K017314/1, BB/H022384/1)
- National Institute on Aging (R01AG053832, R01AG013925, R37AG013925)
- National Heart, Lung, and Blood Institute (R01-HL-092961)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- cellular senescence, idiopathic pulmonary fibrosis, senolytics, senescence-associated secretory phenotype, senescent fibroblasts, p16, bleomycin-induced lung injury, interstitial pulmonary fibrosis, suicide gene therapy, lung function
- MeSH terms
- Animals, Bleomycin, Fibroblasts, Humans, Lung, Male, Biomarkers, Cellular Senescence, Cyclin-Dependent Kinase Inhibitor p16, Proteome, Mice, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.